Target Gene/Pathway
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z other
No. | KEGG PATHWAY * On map, Yellow: Drug target, Red: Disease-related |
KEGG GENES * [Number of genes] |
KEGG DRUG * | DrugBank | Disease ID * [Number of diseases] |
1 | Acute myeloid leukemia |
[1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
2 | Adipocytokine signaling pathway |
[1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
[1] TNF | D00754 | Thalidomide | [18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 | ||
3 | African trypanosomiasis |
[1] TNF | D00754 | Thalidomide | [18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
4 | AGE-RAGE signaling pathway in diabetic complications |
[1] TNF | D00754 | Thalidomide | [18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
[1] VEGFA | D06409 | Bevacizumab | [9] 13, 34, 85, 86, 87, 89, 227, 280, 331 | ||
5 | Allograft rejection |
[1] TNF | D00754 | Thalidomide | [18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
6 | Alzheimer disease |
[1] TNF | D00754 | Thalidomide | [18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
7 | Amoebiasis |
[1] TNF | D00754 | Thalidomide | [18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
8 | AMPK signaling pathway |
[1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
9 | Amyotrophic lateral sclerosis (ALS) |
[1] TNF | D00754 | Thalidomide | [18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
10 | Antifolate resistance |
[1] TNF | D00754 | Thalidomide | [18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
11 | Antigen processing and presentation |
[1] TNF | D00754 | Thalidomide | [18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
12 | Apelin signaling pathway |
[1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
13 | Apoptosis |
[1] TNF | D00754 | Thalidomide | [18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
14 | Asthma |
[1] TNF | D00754 | Thalidomide | [18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
15 | Autophagy - animal |
[1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
16 | Autophagy - other |
[1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
17 | Bladder cancer |
[1] VEGFA | D06409 | Bevacizumab | [9] 13, 34, 85, 86, 87, 89, 227, 280, 331 |
18 | Breast cancer |
[1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
19 | C-type lectin receptor signaling pathway |
[1] TNF | D00754 | Thalidomide | [18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
20 | Cellular senescence |
[1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
21 | Central carbon metabolism in cancer |
[1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
22 | cGMP-PKG signaling pathway |
[3] ADRA2A, ADRA2B, ADRA2C | D00514 | Dexmedetomidine | [11] 2, 4, 6, 21, 34, 70, 113, 212, 215, 226, 280 |
D01205 | |||||
23 | Chagas disease (American trypanosomiasis) |
[1] TNF | D00754 | Thalidomide | [18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
24 | Choline metabolism in cancer |
[1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
25 | Colorectal cancer |
[1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
26 | Complement and coagulation cascades |
[1] SERPINC1 | D07510 | Heparin | [11] 60, 70, 79, 84, 107, 224, 226, 280, 299, 316, 317 |
27 | Cytokine-cytokine receptor interaction |
[1] TNF | D00754 | Thalidomide | [18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
28 | Dilated cardiomyopathy (DCM) |
[1] TNF | D00754 | Thalidomide | [18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
29 | EGFR tyrosine kinase inhibitor resistance |
[1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
[1] VEGFA | D06409 | Bevacizumab | [9] 13, 34, 85, 86, 87, 89, 227, 280, 331 | ||
30 | Endocrine resistance |
[1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
31 | Epstein-Barr virus infection |
[1] TNF | D00754 | Thalidomide | [18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
32 | ErbB signaling pathway |
[1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
33 | Estrogen signaling pathway |
[1] OPRM1 | D00845 | Sufentanil | [1] 280 |
D05938 | |||||
34 | Fc epsilon RI signaling pathway |
[1] TNF | D00754 | Thalidomide | [18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
35 | Fluid shear stress and atherosclerosis |
[1] TNF | D00754 | Thalidomide | [18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
[1] VEGFA | D06409 | Bevacizumab | [9] 13, 34, 85, 86, 87, 89, 227, 280, 331 | ||
36 | Focal adhesion |
[1] VEGFA | D06409 | Bevacizumab | [9] 13, 34, 85, 86, 87, 89, 227, 280, 331 |
37 | Gastric cancer |
[1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
38 | Glioma |
[1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
39 | Graft-versus-host disease |
[1] TNF | D00754 | Thalidomide | [18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
40 | Growth hormone synthesis, secretion and action |
[1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
41 | Hematopoietic cell lineage |
[1] TNF | D00754 | Thalidomide | [18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
42 | Hepatitis B |
[1] TNF | D00754 | Thalidomide | [18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
43 | Hepatitis C |
[1] TNF | D00754 | Thalidomide | [18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
44 | Hepatocellular carcinoma |
[1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
45 | Herpes simplex virus 1 infection |
[1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
[1] TNF | D00754 | Thalidomide | [18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 | ||
46 | HIF-1 signaling pathway |
[1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
[1] VEGFA | D06409 | Bevacizumab | [9] 13, 34, 85, 86, 87, 89, 227, 280, 331 | ||
47 | Human cytomegalovirus infection |
[1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
[1] TNF | D00754 | Thalidomide | [18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 | ||
[1] VEGFA | D06409 | Bevacizumab | [9] 13, 34, 85, 86, 87, 89, 227, 280, 331 | ||
48 | Human immunodeficiency virus 1 infection |
[1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
[1] TNF | D00754 | Thalidomide | [18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 | ||
49 | Human papillomavirus infection |
[1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
[1] TNF | D00754 | Thalidomide | [18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 | ||
[1] VEGFA | D06409 | Bevacizumab | [9] 13, 34, 85, 86, 87, 89, 227, 280, 331 | ||
50 | Human T-cell leukemia virus 1 infection |
[1] TNF | D00754 | Thalidomide | [18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
51 | Hypertrophic cardiomyopathy (HCM) |
[1] TNF | D00754 | Thalidomide | [18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
52 | IL-17 signaling pathway |
[1] TNF | D00754 | Thalidomide | [18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
53 | Inflammatory bowel disease (IBD) |
[1] TNF | D00754 | Thalidomide | [18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
54 | Influenza A |
[1] TNF | D00754 | Thalidomide | [18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
55 | Insulin resistance |
[1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
[1] TNF | D00754 | Thalidomide | [18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 | ||
56 | Insulin signaling pathway |
[1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
57 | JAK-STAT signaling pathway |
[1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
58 | Kaposi sarcoma-associated herpesvirus infection |
[1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
[1] VEGFA | D06409 | Bevacizumab | [9] 13, 34, 85, 86, 87, 89, 227, 280, 331 | ||
59 | Legionellosis |
[1] TNF | D00754 | Thalidomide | [18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
60 | Leishmaniasis |
[1] TNF | D00754 | Thalidomide | [18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
61 | Longevity regulating pathway |
[1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
62 | Longevity regulating pathway - multiple species |
[1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
63 | Malaria |
[1] TNF | D00754 | Thalidomide | [18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
64 | MAPK signaling pathway |
[1] TNF | D00754 | Thalidomide | [18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
[1] VEGFA | D06409 | Bevacizumab | [9] 13, 34, 85, 86, 87, 89, 227, 280, 331 | ||
65 | MicroRNAs in cancer |
[1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
[1] VEGFA | D06409 | Bevacizumab | [9] 13, 34, 85, 86, 87, 89, 227, 280, 331 | ||
66 | Morphine addiction |
[1] OPRM1 | D00845 | Sufentanil | [1] 280 |
D05938 | |||||
67 | mTOR signaling pathway |
[1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
[1] TNF | D00754 | Thalidomide | [18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 | ||
68 | Natural killer cell mediated cytotoxicity |
[1] TNF | D00754 | Thalidomide | [18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
69 | Necroptosis |
[1] TNF | D00754 | Thalidomide | [18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
70 | Neuroactive ligand-receptor interaction |
[3] ADRA2A, ADRA2B, ADRA2C | D00514 | Dexmedetomidine | [11] 2, 4, 6, 21, 34, 70, 113, 212, 215, 226, 280 |
D01205 | |||||
[1] OPRM1 | D00845 | Sufentanil | [1] 280 | ||
D05938 | |||||
71 | NF-kappa B signaling pathway |
[1] TNF | D00754 | Thalidomide | [18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
72 | NOD-like receptor signaling pathway |
[1] TNF | D00754 | Thalidomide | [18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
73 | Non-alcoholic fatty liver disease (NAFLD) |
[1] TNF | D00754 | Thalidomide | [18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
74 | Osteoclast differentiation |
[1] TNF | D00754 | Thalidomide | [18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
75 | Pancreatic cancer |
[1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
[1] VEGFA | D06409 | Bevacizumab | [9] 13, 34, 85, 86, 87, 89, 227, 280, 331 | ||
76 | Pathogenic Escherichia coli infection |
[1] TNF | D00754 | Thalidomide | [18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
77 | Pathways in cancer |
[1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
[1] VEGFA | D06409 | Bevacizumab | [9] 13, 34, 85, 86, 87, 89, 227, 280, 331 | ||
78 | PD-L1 expression and PD-1 checkpoint pathway in cancer |
[1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
79 | Pertussis |
[1] TNF | D00754 | Thalidomide | [18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
80 | Phospholipase D signaling pathway |
[1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
81 | PI3K-Akt signaling pathway |
[1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
[1] VEGFA | D06409 | Bevacizumab | [9] 13, 34, 85, 86, 87, 89, 227, 280, 331 | ||
82 | Prostate cancer |
[1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
83 | Proteoglycans in cancer |
[1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
[1] TNF | D00754 | Thalidomide | [18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 | ||
[1] VEGFA | D06409 | Bevacizumab | [9] 13, 34, 85, 86, 87, 89, 227, 280, 331 | ||
84 | Rap1 signaling pathway |
[1] VEGFA | D06409 | Bevacizumab | [9] 13, 34, 85, 86, 87, 89, 227, 280, 331 |
85 | Ras signaling pathway |
[1] VEGFA | D06409 | Bevacizumab | [9] 13, 34, 85, 86, 87, 89, 227, 280, 331 |
86 | Relaxin signaling pathway |
[1] VEGFA | D06409 | Bevacizumab | [9] 13, 34, 85, 86, 87, 89, 227, 280, 331 |
87 | Renal cell carcinoma |
[1] VEGFA | D06409 | Bevacizumab | [9] 13, 34, 85, 86, 87, 89, 227, 280, 331 |
88 | Rheumatoid arthritis |
[1] TNF | D00754 | Thalidomide | [18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
[1] VEGFA | D06409 | Bevacizumab | [9] 13, 34, 85, 86, 87, 89, 227, 280, 331 | ||
89 | RIG-I-like receptor signaling pathway |
[1] TNF | D00754 | Thalidomide | [18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
90 | Shigellosis |
[1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
[1] TNF | D00754 | Thalidomide | [18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 | ||
91 | Sphingolipid signaling pathway |
[1] TNF | D00754 | Thalidomide | [18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
92 | Systemic lupus erythematosus |
[1] TNF | D00754 | Thalidomide | [18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
93 | T cell receptor signaling pathway |
[1] TNF | D00754 | Thalidomide | [18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
94 | TGF-beta signaling pathway |
[1] TNF | D00754 | Thalidomide | [18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
95 | Th17 cell differentiation |
[1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
96 | Thermogenesis |
[1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
97 | Thyroid hormone signaling pathway |
[1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
98 | TNF signaling pathway |
[1] TNF | D00754 | Thalidomide | [18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
99 | Toll-like receptor signaling pathway |
[1] TNF | D00754 | Thalidomide | [18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
100 | Toxoplasmosis |
[1] TNF | D00754 | Thalidomide | [18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
101 | Tuberculosis |
[1] TNF | D00754 | Thalidomide | [18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
102 | Type I diabetes mellitus |
[1] TNF | D00754 | Thalidomide | [18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
103 | Type II diabetes mellitus |
[1] MTOR | D00753 | Sirolimus | [36] 2, 13, 15, 17, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 85, 86, 89, 96, 98, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 |
[1] TNF | D00754 | Thalidomide | [18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 | ||
104 | VEGF signaling pathway |
[1] VEGFA | D06409 | Bevacizumab | [9] 13, 34, 85, 86, 87, 89, 227, 280, 331 |
105 | Viral protein interaction with cytokine and cytokine receptor |
[1] TNF | D00754 | Thalidomide | [18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
106 | Yersinia infection |
[1] TNF | D00754 | Thalidomide | [18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |